trastuzumab
Trastuzumab - an overview
trastuzumab ให้ครั้งแรก 4mgkg และให้ต่อ 2mgkg ทุกสัปดาห์จนกระทั่งมี disease progression หรือมี unacceptable toxicity ยา capecitabineในมะเร็งเต้านมระยะที่ 4 สรุปคำแนะนำ ควร
Cardiotoxicity Trastuzumab is a monoclonal antibody tyrosine kinase inhibitor that targets the HER2 receptor often over overexpressed or overactive in breast Trastuzumab, a humanized monoclonal antibody against the ectodomain of HER2 Trastuzumab uses multiple mechanisms to interfere with HER2 downstream
ไฮยีน่า CONCLUSION: Administering higher doses on a 3-weekly schedule did not compromise the efficacy and safety of trastuzumab in women with HER2-positive MBC, and trastuzumab beyond progression Trastuzumab is generally well tolerated and does not cause many of the toxicities or side effects seen with conventional
